Human tissue samples linked by microfluidic channels replicate interactions of multiple organs.
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time, allowing them to measure the effects of drugs on different parts of the body.
Such a system could reveal, for example, whether a drug that is intended to treat one organ will have adverse effects on another.
“Some of these effects are really hard to predict from animal models because the situations that lead to them are idiosyncratic,” says Linda Griffith, the School of Engineering Professor of Teaching Innovation, a professor of biological engineering and mechanical engineering, and one of the senior authors of the study. “With our chip, you can distribute a drug and then look for the effects on other tissues, and measure the exposure and how it is metabolized.”
These chips could also be used to evaluate antibody drugs and other immunotherapies, which are difficult to test thoroughly in animals because they are designed to interact with the human immune system.
David Trumper, an MIT professor of mechanical engineering, and Murat Cirit, a research scientist in the Department of Biological Engineering, are also senior authors of the paper, which appears in the journal Scientific Reports. The paper’s lead authors are former MIT postdocs Collin Edington and Wen Li Kelly Chen.
When developing a new drug, researchers identify drug targets based on what they know about the biology of the disease, and then create compounds that affect those targets. Preclinical testing in animals can offer information about a drug’s safety and effectiveness before human testing begins, but those tests may not reveal potential side effects, Griffith says. Furthermore, drugs that work in animals often fail in human trials.
“Animals do not represent people in all the facets that you need to develop drugs and understand disease,” Griffith says. “That is becoming more and more apparent as we look across all kinds of drugs.”
Complications can also arise due to variability among individual patients, including their genetic background, environmental influences, lifestyles, and other drugs they may be taking. “A lot of the time you don’t see problems with a drug, particularly something that might be widely prescribed, until it goes on the market,” Griffith says.
As part of a project spearheaded by the Defense Advanced Research Projects Agency (DARPA), Griffith and her colleagues decided to pursue a technology that they call a “physiome on a chip,” which they believe could offer a way to model potential drug effects more accurately and rapidly. To achieve this, the researchers needed new equipment — a platform that would allow tissues to grow and interact with each other — as well as engineered tissue that would accurately mimic the functions of human organs.
Before this project was launched, no one had succeeded in connecting more than a few different tissue types on a platform. Furthermore, most researchers working on this kind of chip were working with closed microfluidic systems, which allow fluid to flow in and out but do not offer an easy way to manipulate what is happening inside the chip. These systems also require external pumps.
The MIT team decided to create an open system, which essentially removes the lid and makes it easier to manipulate the system and remove samples for analysis. Their system, adapted from technology they previously developed and commercialized through U.K.-based CN BioInnovations, also incorporates several on-board pumps that can control the flow of liquid between the “organs,” replicating the circulation of blood, immune cells, and proteins through the human body. The pumps also allow larger engineered tissues, for example tumors within an organ, to be evaluated.
The researchers created several versions of their chip, linking up to 10 organ types: liver, lung, gut, endometrium, brain, heart, pancreas, kidney, skin, and skeletal muscle. Each “organ” consists of clusters of 1 million to 2 million cells. These tissues don’t replicate the entire organ, but they do perform many of its important functions. Significantly, most of the tissues come directly from patient samples rather than from cell lines that have been developed for lab use. These so-called “primary cells” are more difficult to work with but offer a more representative model of organ function, Griffith says.
Using this system, the researchers showed that they could deliver a drug to the gastrointestinal tissue, mimicking oral ingestion of a drug, and then observe as the drug was transported to other tissues and metabolized. They could measure where the drugs went, the effects of the drugs on different tissues, and how the drugs were broken down. In a related publication, the researchers modeled how drugs can cause unexpected stress on the liver by making the gastrointestinal tract “leaky,” allowing bacteria to enter the bloodstream and produce inflammation in the liver.
Kevin Healy, a professor of bioengineering and materials science and engineering at the University of California at Berkeley, says that this kind of system holds great potential for accurate prediction of complex adverse drug reactions.
“While microphysiological systems (MPS) featuring single organs can be of great use for both pharmaceutical testing and basic organ-level studies, the huge potential of MPS technology is revealed by connecting multiple organ chips in an integrated system for in vitro pharmacology. This study beautifully illustrates that multi-MPS “physiome-on-a-chip” approaches, which combine the genetic background of human cells with physiologically relevant tissue-to-media volumes, allow accurate prediction of drug pharmacokinetics and drug absorption, distribution, metabolism, and excretion,” says Healy, who was not involved in the research.
Griffith believes that the most immediate applications for this technology involve modeling two to four organs. Her lab is now developing a model system for Parkinson’s disease that includes brain, liver, and gastrointestinal tissue, which she plans to use to investigate the hypothesis that bacteria found in the gut can influence the development of Parkinson’s disease.
Other applications include modeling tumors that metastasize to other parts of the body, she says.
“An advantage of our platform is that we can scale it up or down and accommodate a lot of different configurations,” Griffith says. “I think the field is going to go through a transition where we start to get more information out of a three-organ or four-organ system, and it will start to become cost-competitive because the information you’re getting is so much more valuable.”
Learn more: “Body on a chip” could improve drug evaluation
The Latest on: Body-on-a-chip
via Google News
The Latest on: Body-on-a-chip
- After cancer diagnosis, Wyoming police officer warns about danger of smoking on November 13, 2018 at 5:57 pm
BILLINGS – We are all, at one point or another, guilty of feeling invincible. That the problems other people face will not make their way into our lives. Wyoming police officer C.S. Dickey ... […]
- 'Every challenge is a blessing': Educator diagnosed with cancer climbs Mount Everest on November 13, 2018 at 5:22 pm
An education administrator took his fight against cancer to new heights, raising money for a cure by climbing Mount Everest. In 2016, Jim Detwiler, who is deputy superintendent of Boone County Schools ... […]
- New Orleans guitarist Spencer Bohren diagnosed with cancer on November 13, 2018 at 2:28 pm
Spencer Bohren isn’t going anywhere. It’s an odd thing to look at the calendar and not see it speckled with names of far-off places where the New Orleans musician will go to thumb his guitar. But ther... […]
- He Never Smoked a Day in His Life. At 28, He Was Diagnosed With Lung Cancer. on November 13, 2018 at 10:46 am
Stephen Huff grew up living and breathing baseball in Tennessee. He earned a college scholarship to as a pitcher to Austin Peay State University, where he was drafted by the Chicago White Sox. He was ... […]
- Bryan Health Second Sunday Report: Lincoln woman lives, despite terminal lung cancer diagnosis on November 13, 2018 at 9:58 am
In the last ten years Rose Porto, of Lincoln, has seen her children get married; she’s celebrated birthdays, welcomed grandchildren and watched them grow. Memories she didn't think she'd be around to ... […]
- November is Pancreatic Cancer Awareness Month – do you know the symptoms? on November 13, 2018 at 9:37 am
November is Pancreatic Cancer Awareness Month. Pancreatic cancer is one of the nation’s deadliest cancers with a five-year survival rate of just 9 percent. It’s a disease that kills more people than b... […]
- NeNe Leakes Reveals How Her Son Brentt Leakes Is Dealing with His Dad Gregg Leakes' Cancer Diagnosis on November 13, 2018 at 7:54 am
NeNe Leakes and Gregg Leakes are taking viewers inside their very personal crisis as The Real Housewives of Atlanta husband deals with a cancer diagnosis this season. And NeNe has been quite open abou... […]
- Genomics provide hope for those with 'one in a million' cancer diagnosis on November 13, 2018 at 7:35 am
New research has shown that many Australians with rare cancers can benefit from genomic profiling. The findings of the patient-driven trial are being presented today at the Clinical Oncology ... […]
- 'Devastating cancer diagnosis means I must say goodbye to a husband and father' on November 13, 2018 at 6:21 am
Karen Ferris, from Clonmel, Co Tipperary, is caring for her husband Martin who is in the final stage of his fight against pancreatic cancer in Marymount Hospital in Cork. "While I now want peace for M... […]
via Bing News